Crossmark

Visible light induces skin darkening in vivo: comparative pilot studies reveal enhanced susceptibility in melasma and its mitigation by a human tyrosinase inhibitor

Crossref DOI link: https://doi.org/10.1007/s43630-025-00844-2

Published Online: 2026-01-19

Published Print: 2026-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Mann, Tobias

Eggers, Kerstin

Rogers, Tamara

Riedel, Julia

Lütgens, Manuela

Thiele, Lisa

Möller, Nadine

Weise, Julia M.

Kolbe, Ludger https://orcid.org/0000-0001-8608-8901
License Information

Text and Data Mining valid from 2026-01-19

Version of Record valid from 2026-01-19
More Information

Article History

Received: 15 July 2025

Accepted: 24 December 2025

First Online: 19 January 2026

Declarations

:

: The authors are employees of Beiersdorf AG. Thiamidol is patented by Beiersdorf AG.

: Reviewed and approved by the institutional review board of Beiersdorf AG (Hamburg, Germany); approval # STDY-062419, STDY-062514, STDY-063945.

: The patients in this manuscript have given written informed consent to the publication of their case details.

Document is current

Any future updates will be listed below